Phase Ib/II Clinical Study of SHR-8068 Combined With Adebrelimab and Other Anti-tumor Drugs in the Treatment of Advanced Renal Cell Carcinom

Trial Details

NCT ID

NCT07239596

Phase

PHASE1 / PHASE2

Sponsor

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Status

RECRUITING

Cancer Type

Kidney Cancer

Interventions

• SHR-8068；Adebrelimab ；Bevacizumab
• SHR-8068；Adebrelimab ；HS-10516
• SHR-8068； Adebrelimab ； Bevacizumab ；HRS-10516

Locations (sample)

• Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

• Age 18 to 75 years old (including boundary values)
• Volunteer to participate in this clinical study and sign informed consent;
• ECOG score 0-1;
• Expected survival ≥3 months;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.